Two medicines, side by side
Abaloparatide vs atenolol
Abaloparatide is labeled for osteoporosis; atenolol for high blood pressure, angina and heart attack and coronary artery disease. Their labels share no use, so they are not alternatives to each other. Drugs@FDA records approvals of abaloparatide since 2017 and of atenolol since 1981. In FDA's classes, abaloparatide is a parathyroid hormone-related peptide analog and atenolol a beta-adrenergic blocker.
Check it at the source: the abaloparatide FDA label on DailyMed (effective August 11, 2026); the atenolol FDA label on DailyMed (effective September 18, 2025).
Highlights of the abaloparatide record
Abaloparatide (Tymlos) · label of August 11, 2026
Used for
From the label: indicationsTYMLOS is a human parathyroid hormone related peptide [PTHrP(1-34)] analog indicated for the: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy. […]
On the market
- Earliest approval on file
- April 28, 2017
- Generic labelers
- none listed
- Pharmacy cost
- Not in the survey
Supply and safety
- Shortage
- No current entry
- Recalls
- 0
Highlights of the atenolol record
Atenolol (Tenormin) · label of September 18, 2025
Used for
From the label: indicationsHypertension TENORMIN is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol. […]
On the market
- Earliest approval on file
- August 19, 1981
- Generic labelers
- 35 labelers
- Pharmacy cost
- $0.0217 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 4
Source: FDA drug labels via openFDA (Abaloparatide label of August 11, 2026, Atenolol label of September 18, 2025); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do abaloparatide and atenolol differ on the record?
In FDA's classes, abaloparatide is a parathyroid hormone-related peptide analog and atenolol a beta-adrenergic blocker.
Generics: abaloparatide none approved; atenolol since 1988 (Drugs@FDA).
| Abaloparatide | Atenolol | |
|---|---|---|
| Labeled for | Osteoporosis | High blood pressure, Angina, Heart attack and coronary artery disease |
| Pharmacologic class | Parathyroid Hormone-Related Peptide Analog | beta-Adrenergic Blocker |
| How it works (label) | Abaloparatide is a PTHrP(1-34) analog which acts as an agonist at the PTH1 receptor (PTH1R). This results in activation of the cAMP signaling pathway in target cells. | n/a |
| Half-life (label) | n/a | The elimination half-life of oral TENORMIN is approximately 6 to 7 hours, and there is no alteration of the kinetic profile of the drug by chronic administration. |
| Earliest approval on file (Drugs@FDA) | April 28, 2017 | August 19, 1981 |
| First generic approved | none | July 15, 1988 |
| Generic labelers (NDC) | none listed | 35 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | n/a | $0.0217 per tablet (Atenolol 25 mg tablet) |
| 12-month price change | n/a | -3% |
| Boxed warning | No | No |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 0 | 4 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 29,258 | 132,491 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to abaloparatide
- every medicine labeled for the same conditions